Literature DB >> 24009127

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Grzegorz Helbig1, Sławomira Kyrcz-Krzemień.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24009127     DOI： 10.1002/ajh.23588

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

Authors:  Melanie C Dispenza; Bruce S Bochner
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 2.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

3.  Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.

Authors:  P Khoury; R Desmond; A Pabon; N Holland-Thomas; J M Ware; D C Arthur; R Kurlander; M P Fay; I Maric; A D Klion
Journal:  Allergy       Date:  2016-03-02       Impact factor: 13.146

4.  Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass.

Authors:  Amy S Duffield; Jonathan Webster; B Douglas Smith; Julius S Necciai; Austin McCuiston; Alisha D Ware
Journal:  Head Neck Pathol       Date:  2021-02-22

5.  Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.

Authors:  Shi-Qiang Qu; Tie-Jun Qin; Ze-Feng Xu; Yue Zhang; Xiao-Fei Ai; Bing Li; Hong-Li Zhang; Li-Wei Fang; Li-Juan Pan; Nai-Bo Hu; Zhi-Jian Xiao
Journal:  Oncotarget       Date:  2016-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.